WO2010074541A2 - Zz 도메인을 이용한 약물전달체 - Google Patents

Zz 도메인을 이용한 약물전달체 Download PDF

Info

Publication number
WO2010074541A2
WO2010074541A2 PCT/KR2009/007806 KR2009007806W WO2010074541A2 WO 2010074541 A2 WO2010074541 A2 WO 2010074541A2 KR 2009007806 W KR2009007806 W KR 2009007806W WO 2010074541 A2 WO2010074541 A2 WO 2010074541A2
Authority
WO
WIPO (PCT)
Prior art keywords
domain
drug delivery
delivery carrier
targeting moiety
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/007806
Other languages
English (en)
French (fr)
Other versions
WO2010074541A3 (ko
Inventor
이상경
김나현
쿠마프리티
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry University Cooperation Foundation IUCF HYU
Original Assignee
Industry University Cooperation Foundation IUCF HYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry University Cooperation Foundation IUCF HYU filed Critical Industry University Cooperation Foundation IUCF HYU
Publication of WO2010074541A2 publication Critical patent/WO2010074541A2/ko
Publication of WO2010074541A3 publication Critical patent/WO2010074541A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 (a) ZZ 도메인; 및 (b) 항체의 Fc 부위를 포함하며 세포의 표면 분자(cell surface molecule)에 결합하는 상기 ZZ 도메인에 결합된 타겟팅 모이어티(targeting moiety)를 포함하는 약물전달체에 관한 것이다. 본 발명에 따르면, 항체(예컨대, IgG)의 Fc 부위에 결합하는 ZZ 도메인의 특징을 이용하여 표적하는 세포 표면물질(예컨대, 수용체)과 결합하는 타겟팅 모이어티(예컨대, 항체)를 ZZ 도메인과 결합시켜 전달하면 타겟팅 모이어티만 교체함으로써 다양한 세포로 약물을 전달할 수 있다. 본 발명의 약물전달체는 운반대상의 카고에 따라, 질병 또는 질환의 치료, 특정 세포의 검출, 질병(예컨대, 암)의 진단, 특정 세포의 위치 추적 및 인 비보 이미징 등에 이용될 수 있다.
PCT/KR2009/007806 2008-12-26 2009-12-24 Zz 도메인을 이용한 약물전달체 Ceased WO2010074541A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0134141 2008-12-26
KR20080134141 2008-12-26

Publications (2)

Publication Number Publication Date
WO2010074541A2 true WO2010074541A2 (ko) 2010-07-01
WO2010074541A3 WO2010074541A3 (ko) 2010-10-14

Family

ID=42288328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007806 Ceased WO2010074541A2 (ko) 2008-12-26 2009-12-24 Zz 도메인을 이용한 약물전달체

Country Status (1)

Country Link
WO (1) WO2010074541A2 (ko)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JAHNS, A.C. ET AL.: 'Multifunctional inorganic-binding beads self-assembled inside engineered bacteria' BIOCONJUG. CHEM. vol. 19, no. 10, October 2008, pages 2072 - 2080 *
KURATA, N. ET AL.: 'Specific protein delivery to target cells by antibody-displaying bionanocapsules' J BIOCHEM. vol. 144, no. 6, 06 October 2008, pages 701 - 707 *
MASOOD R. ET AL.: 'Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors' INT. J. MOL. MED. vol. 8, no. 4, October 2001, pages 335 - 343 *
OJALA K. ET AL.: 'Improved display of synthetic IgG-binding domains on the baculovirus surface' TECHNOL. CANCER RES. TREAT. vol. 3, no. 1, February 2004, pages 77 - 84 *
SONG E. ET AL.: 'Antibody mediated in vivo delivery of small interfering RNAs via cell- surface receptors' NAT. BIOTECHNOL. vol. 23, no. 6, 2005, pages 709 - 717 *
WHITE P.J.: 'Barriers to successful delivery of short interfering RNA after systemic administration' CLIN. EXP. PHARMACOL. PHYSIOL. vol. 35, no. 11, November 2008, pages 1371 - 1376 *

Also Published As

Publication number Publication date
WO2010074541A3 (ko) 2010-10-14

Similar Documents

Publication Publication Date Title
Conilh et al. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform
Lindberg et al. Progress and future directions with peptide-drug conjugates for targeted cancer therapy
Wang et al. Development and properties of valine-alanine based antibody-drug conjugates with monomethyl auristatin E as the potent payload
Deonarain et al. Small-format drug conjugates: a viable alternative to ADCs for solid tumours?
Han et al. The potential of topoisomerase inhibitor-based antibody–drug conjugates
Sun et al. Reduction− alkylation strategies for the modification of specific monoclonal antibody disulfides
Stiltner et al. Cell-penetrating peptides: Applications in tumor diagnosis and therapeutics
JP6810146B2 (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
Shigdar et al. Profiling cancer cells by cell-SELEX: use of aptamers for discovery of actionable biomarkers and therapeutic applications thereof
Luo et al. Lysosome targeting chimaeras for Glut1-facilitated targeted protein degradation
Sokolowska-Wedzina et al. High-affinity internalizing human scFv-Fc antibody for targeting FGFR1-overexpressing lung cancer
Bu et al. Inside-out-oriented cell membrane biomimetic magnetic nanoparticles for high-performance drug lead discovery
JP2009536834A5 (ko)
WO2011159847A3 (en) Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
JP2016509582A5 (ko)
Tashima Brain cancer chemotherapy through a delivery system across the blood-brain barrier into the brain based on receptor-mediated transcytosis using monoclonal antibody conjugates
Dokus et al. Phage display-based homing peptide-daunomycin conjugates for selective drug targeting to PANC-1 pancreatic cancer
Salama et al. Targeted protein degradation: clinical advances in the field of oncology
Ding et al. Incorporation of a hydrophilic spacer reduces hepatic uptake of HER2-targeting affibody–DM1 drug conjugates
Reynolds et al. Influence of ligand presentation density on the molecular recognition of mannose-functionalised glyconanoparticles by bacterial lectin BC2L-A
WO2005035550A3 (en) Dual phase-pna conjugates for the delivery of pna through the blood brain barrier
WO2008100482A3 (en) Peptides that target to tumor blood vessels of lung cancer and applications thereof
Cho et al. A tumor-homing peptide platform enhances drug solubility, improves blood–brain barrier permeability and targets glioblastoma
CN111971060A (zh) 募集抗体并靶向肿瘤细胞的双功能分子
Agnello et al. Aptamer-based strategies to boost immunotherapy in TNBC

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835307

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09835307

Country of ref document: EP

Kind code of ref document: A2